Patent classifications
C07C255/60
ISOXAZOLINE-SUBSTITUTED BENZAMIDE COMPOUND AND PESTICIDE
An isoxazoline-substituted benzamide compound, and the salt thereof. For example, a compound having the following formula:
##STR00001##
and pesticides characterized by containing the compound as an active ingredient.
ISOXAZOLINE-SUBSTITUTED BENZAMIDE COMPOUND AND PESTICIDE
An isoxazoline-substituted benzamide compound, and the salt thereof. For example, a compound having the following formula:
##STR00001##
and pesticides characterized by containing the compound as an active ingredient.
IMMUNOREGULATORY AGENTS
Compounds that modulate the oxidoreductase enzyme indoleamine 2,3-dioxygenase, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by indoleamine 2,3-dioxygenase is also provided.
IMMUNOREGULATORY AGENTS
Compounds that modulate the oxidoreductase enzyme indoleamine 2,3-dioxygenase, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by indoleamine 2,3-dioxygenase is also provided.
Insecticidal compounds
The present invention relates to novel triazole derivatives of formula (I) having insecticidal activity, to processes and intermediates for preparing them, to insecticidal, acaricidal, nematicidal or molluscicidal compositions comprising them and to methods of using them to combat and control insect, acarine, nematode or mollusc pests ##STR00001## wherein Y, X.sub.1, X.sub.2 and Q are as defined in claim 1; or salts thereof.
Insecticidal compounds
The present invention relates to novel triazole derivatives of formula (I) having insecticidal activity, to processes and intermediates for preparing them, to insecticidal, acaricidal, nematicidal or molluscicidal compositions comprising them and to methods of using them to combat and control insect, acarine, nematode or mollusc pests ##STR00001## wherein Y, X.sub.1, X.sub.2 and Q are as defined in claim 1; or salts thereof.
COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER
This disclosure relates to compounds, pharmaceutical compositions comprising them, and methods of using the compounds and compositions for treating diseases related to Heat Shock Transcription Factor 1 (HSF1) activity and/or function. More particularly, this disclosure relates to methods of inhibiting HSF1 activity with these compounds and pharmaceutical compositions thereof, and methods of treating diseases associated with HSF1 activity and/or function, such as cancer.
HETEROCYCLIC COMPOUND AND USE THEREOF
A heterocyclic compound that can have an antagonistic action on an NMDA receptor containing the NR2B subunit, and is expected to be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like is provided. A compound represented by the formula (I):
##STR00001##
wherein each symbol is as described in the DESCRIPTION, or a salt thereof.
HETEROCYCLIC COMPOUND AND USE THEREOF
A heterocyclic compound that can have an antagonistic action on an NMDA receptor containing the NR2B subunit, and is expected to be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like is provided. A compound represented by the formula (I):
##STR00001##
wherein each symbol is as described in the DESCRIPTION, or a salt thereof.
Pantothenamide analogues
The present invention provides compounds that have antimalarial activity. More in particular, the present invention provides novel compounds that are analogues of pantothenamides. The pantothenamide analogues of this invention have particularly low IC.sub.50 values against the asexual blood stages and gametocytes of malaria parasites. Furthermore, the pantothenamide analogues of this invention are characterized by low hepatic metabolism. Therefore, pantothenamide analogues of the invention are particularly suitable for use in therapeutic and/or prophylactic treatment of protozoan infections in a human or animal subject in need thereof. The invention further provides pharmaceutical formulations comprising the pantothenamide analogues as well as the therapeutic and/or prophylactic uses of the pantothenamide analogues and pharmaceutical formulations comprising them.